Skip to content

Post-market Safety Reassessment of Ulinastatin for Injection

Post-market Safety Reassessment of Ulinastatin for Injection

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02520570
Enrollment
10000
Registered
2015-08-13
Start date
2014-08-31
Completion date
2018-08-31
Last updated
2018-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Reaction to Drug

Brief summary

1. Investigate the application of ulinastatin(UTI) in real practice clinic.(eg:population character, usage and dosage, course of treatment,etc ) 2. Analysis the incidence of adverse drug reactions /adverse events of ulinastatin, collect the main clinical manifestations, treatment, outcome, influence factors; provide evidence for improving the recommended medication plan of ulinastatin. 3. Evaluate the safety of ulinastatin , obtain scientific conclusion , and provide evidence for appropriate medication to administration department of health authority.

Detailed description

In order to find out the application of ulinastatin in real practice clinic , identify the high risk group for adverse event/adverse drug reaction and calculate the adverse event/adverse drug reaction incidence rate, a large sample size clinical trial has been designed. This trial is an observational study. The investigators would screen several hospitals from different provinces and prospectively collect the main clinical manifestations,treatment, outcome, influence factors about patients using ulinastatin either in general clinical departments or in ICU. This study would be expected to provide evidence for appropriate medication to administration department of health authority.

Interventions

DRUGulinastatin

We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.

Sponsors

Center for ADR Monitoring of Guangdong
CollaboratorUNKNOWN
Techpool Bio-Pharma Co., Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with ulinastatin treated

Exclusion criteria

* Not applicable

Design outcomes

Primary

MeasureTime frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerabilityparticipants will be followed for the duration of using ulinastatin, an expected average of 7 days

Countries

China

Contacts

Primary Contactmingjuan Hua, Master
huamj@techpool.com.cn+86 020 38972288

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026